Journal article
Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention
European journal of preventive cardiology, Vol.31(15), pp.1878-1887
11/11/2024
DOI: 10.1093/eurjpc/zwae212
PMID: 38916491
Abstract
Aims Lipoprotein(a) [Lp(a)] has demonstrated its association with atherosclerosis and myocardial infarction. However, its role in the development of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) is not clearly established. The aim of this study is to investigate the association between Lp(a) and ISR. Methods and results A retrospective study of adult patients who underwent successful PCI between January 2006 and December 2017 at the three Mayo Clinic sites and had a preprocedural Lp(a) measurement was conducted. Patients were divided into two groups according to the serum Lp(a) concentration [high Lp(a) >= 50 mg/dL and low Lp(a) < 50 mg/dL]. Univariable and multivariable analyses were performed to compare risk of ISR between patients with high Lp(a) vs. those with low Lp(a). A total of 1209 patients were included, with mean age 65.9 +/- 11.7 years and 71.8% were male. Median follow-up after baseline PCI was 8.8 [interquartile range (IQR) 7.4] years. Restenosis was observed in 162 (13.4%) patients. Median serum levels of Lp(a) were significantly higher in patients affected by ISR vs. non-affected cases: 27 (IQR 73.8) vs. 20 (IQR 57.5) mg/dL, P = 0.008. The rate of ISR was significantly higher among patients with high Lp(a) vs. patients with low Lp(a) values (17.0% vs. 11.6%, P = 0.010). High Lp(a) values were independently associated with ISR events (hazard ratio 1.67, 95% confidence interval 1.18-2.37, P = 0.004), and this association was more prominent after the first year following the PCI. Conclusion Lipoprotein(a) is an independent predictor for long-term ISR and should be considered in the evaluation of patients undergoing PCI.
Details
- Title: Subtitle
- Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention
- Creators
- Ahmed K. Mahmoud - Mayo Clinic in ArizonaJuan M. Farina - Mayo Clinic in ArizonaKamal Awad - Mayo Clinic in ArizonaNima Baba Ali - Mayo Clinic in ArizonaMilagros Pereyra - Mayo Clinic in ArizonaIsabel G. Scalia - Mayo Clinic in ArizonaMohammed Tiseer Abbas - Mayo Clinic in ArizonaMohamed N. Allam - Mayo Clinic in ArizonaMoaz A. Kamel - Mayo Clinic in ArizonaAnan A Abu Rmilah - Mayo Clin, Dept Cardiovasc Med, Rochester, MN USAChieh-Ju Chao - Mayo ClinicTimothy Barry - Mayo Clinic in ArizonaSaid Alsidawi - Mayo Clinic in ArizonaSteven J. Lester - Mayo Clinic in ArizonaPeter M. Pollak - Mayo Clinic in FloridaMohamad A. Alkhouli - Mayo ClinicKwan S. Lee - Mayo Clinic in ArizonaEric H. Yang - Mayo Clinic in ArizonaRichard W. Lee - Mayo Clinic in ArizonaJohn P. Sweeney - Mayo Clinic in ArizonaDavid F. Fortuin - Mayo Clinic in ArizonaChadi Ayoub - Mayo Clinic in ArizonaReza Arsanjani - Mayo Clinic in Arizona
- Resource Type
- Journal article
- Publication Details
- European journal of preventive cardiology, Vol.31(15), pp.1878-1887
- DOI
- 10.1093/eurjpc/zwae212
- PMID
- 38916491
- NLM abbreviation
- Eur J Prev Cardiol
- ISSN
- 2047-4873
- eISSN
- 2047-4881
- Publisher
- Oxford Univ Press
- Number of pages
- 10
- Language
- English
- Date published
- 11/11/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984845548402771
Metrics
1 Record Views